Federal Government of the United States has legal proceedings with Gilead because of patents for dokontaktny prevention of HIV

Federal Government of the United States through court tries to prove that Gilead Sciences Inc violated the state patents for a combination tenofovira and emtritsitabina for dokontaktny prevention of HIV infection. Truvada and Descovy from Gilead Sciences Inc are approved according to this indication. Claim to Gilead is submitted in 2019, but trial in Federal district court State of Delaware began on May 2. It is expected that process will last no more than six days. As they say in claim, in the middle of the 2000th years scientists from the Center for control and prevention of diseases (CDC) established that the combination emtritsitabina and tenofovira is effective in...